Dhoot Transmission and Molbio Diagnostics have launched their public issues today, August 10, 2026, with bidding open until August 12. Dhoot Transmission enters the market with strong sentiment linked to its EV component leadership, while Molbio Diagnostics offers exposure to diagnostic technology. Investors should weigh the different risk profiles in automotive and healthcare sectors, including valuation, client concentration, and government dependence, before committing capital.
Investors looking to deploy capital this week have two distinct opportunities as both Dhoot Transmission and Molbio Diagnostics launched their mainboard initial public offerings (IPOs) on August 10, 2026. The bidding window for both companies will remain open until August 12, 2026, with a tentative listing on the stock exchanges scheduled for August 17, 2026.
While both companies are entering the public market simultaneously, they operate in completely different sectors, making a direct comparison difficult without looking at their specific business models, financials, and risk factors.
Automotive Focus vs. Healthcare Technology
Dhoot Transmission is a established player in the automotive component space, specifically known for its electrical wiring harnesses. The company holds a significant position in the market, claiming approximately 70% market share in wiring harnesses for electric two- and three-wheelers. This focus on the electric vehicle (EV) segment has been a major talking point, as investors often view EV-related auto parts as a high-growth area. For the fiscal year ending in 2026, the company reported revenues of Rs 4,524.9 crore and a net profit of Rs 396.8 crore.
On the other hand, Molbio Diagnostics operates in the healthcare technology space. Its primary business is built around the Truenat platform, which provides rapid, portable PCR-based diagnostic tests. The company follows a model often described as razor-and-blade, where the initial diagnostic device is sold, followed by recurring sales of testing consumables. Molbio reported FY26 revenue of Rs 1,445.6 crore with a net profit of Rs 164.1 crore.
Financials and Valuation Check
When evaluating the pricing, Dhoot Transmission is entering the market with a price band of Rs 829–871 per share, while Molbio Diagnostics has set its band at Rs 768–807 per share. In terms of valuation, Molbio Diagnostics comes in with a pre-IPO price-to-earnings (P/E) ratio of approximately 55.4 times, whereas Dhoot Transmission trades at around 41.4 times its earnings. Valuation levels like these are important to compare against peers in their respective industries to determine if the pricing is reasonable.
Market sentiment, often gauged through the grey market premium (GMP), has shown differences between the two. Dhoot Transmission has generally attracted higher premiums, reflecting investor optimism regarding its position in the EV supply chain. Molbio’s premiums have shown more variation, which can happen when investors weigh the company's reliance on specific technology cycles or government diagnostic procurement policies.
Risks to Consider
Every IPO carries specific risks that investors should examine. For Dhoot Transmission, a primary concern is customer concentration. The company’s top 10 clients contribute a large portion of its revenue (approximately 81%), meaning the loss of a major contract could significantly impact its financial health. Additionally, as an auto component maker, it is exposed to the volatility of raw material prices.
For Molbio Diagnostics, the risks are different. The business relies heavily on government procurement and the widespread adoption of its specific diagnostic platform. Changes in healthcare spending or delays in regulatory approvals for new tests could affect revenue. Both companies also face execution risks regarding the use of their IPO proceeds, as they plan to use these funds for expansion and debt reduction.
As the subscription period progresses, the final interest levels from retail and institutional investors will provide more clarity on the market's appetite for these two different stories. Investors may want to track the daily subscription figures and any updates from management regarding order books or business expansion plans as they head toward the listing date.